explore -WSS

explore

author：entertainment 2025-09-30 12:18:25 - browse：34335

Vertex Pharmaceuticals - sunset — Bill Sikes/AP

LONDON — Regulators in the U.K. on Thursday approved a CRISPR-based medicine to treat both sickle cell disease and beta thalassemia, making it the world’s first therapy built on the revolutionary gene-editing technology and ushering in a new era of genetic medicine.

The authorization of the therapy, from Vertex Pharmaceuticals and CRISPR Therapeutics, is itself not a surprise. Clinical trials have shown the one-time treatment enabled many sickle cell patients to live free of debilitating pain crises and relieved thalassemia patients of needing regular blood transfusions, raising hopes that they have been effectively cured. But it also stands as a major achievement, coming just over a decade after the first and seminal lab experiments that showed CRISPR’s potential as a gene-editing tool were published.

In granting conditional approval to the therapy, which will have the brand name Casgevy and is also known as exa-cel, the U.K.’s Medicines and Healthcare products Regulatory Agency jumped ahead of its counterparts in the U.S. and Europe, which are also reviewing the medicine, in greenlighting the globe’s first CRISPR treatment. The MHRA’s authorization is for patients who are at least 12 years old.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Medicare must police algorithms in Medicare Advantage, Dems say

hotspot

knowledge

WSS

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

Medicare proceeds with plan to claw back hospital funds

Readout LOUD podcast: ESMO highlights & Roivant's big deal

RaDonda Vaught links Vanderbilt hospital issues to patient death

Gene therapy’s promise and the high cost of hope

entertainment

explore

Wikipedia

Novavax promises a turnaround & Lilly roils the obesity market

Prime Medicine says its gene editing passes test in monkeys

After affirmative action ruling, medical educators look to 'holistic review'

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Novavax promises a turnaround & Lilly roils the obesity market

EPA limits use of carcinogenic gas for sterilizing medical devices

Walensky prepares to leave CDC — and Congress — behind

President Biden's budget: Here's what you might have missed

Malaria cases in Florida and Texas: Here’s what you need to know

How to save health care price transparency rules

focus

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

Travis Kelce and the trap of celebrity vaccine endorsements

DeepMind touts AlphaFold's new skills as protein folding AI models face off

Gene therapy’s promise and the high cost of hope

Sarepta Duchenne therapy fails to meet primary endpoint in trial

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

knowledge

hotspot

knowledge

leisure time